Josh Bilenker, M.D., and Jeff Engelman M.D., Ph.D., have joined forces to create a new cancer biotech, tapping their combined considerable experience to find new solutions to old oncology research problems.
Together, they have created Treeline Biosciences, which “will prioritize molecular targets in oncology that are validated but difficult to drug. If successful, we believe that our approaches could apply to other therapeutic areas as well.”